Leon Murphy
17Patents
8h-index
54Co-inventors
71Inventor score
Filing activity: Feb 19, 2008 → Jun 25, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9815901B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 80 | Active |
| US10174095B2 | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 27 | Active |
| US10287354B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 21 | Active |
| US9370508B2 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors | Human Necessities | 12 | Active |
| US10004803B2 | Low, immune enhancing, dose mtor inhibitors and uses thereof | Chemistry; Metallurgy | 10 | Active |
| US9358236B2 | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases | Human Necessities | 8 | Active |
| US10286069B2 | Low, immune enhancing, dose MTOR inhibitors and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US11084880B2 | Anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 8 | Active |
| US10357514B2 | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | Chemistry; Metallurgy | 7 | Active |
| US10568947B2 | Treatment of cancer using a CLL-1 chimeric antigen receptor | Chemistry; Metallurgy | 1 | Active |
| US10774388B2 | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | Physics | 1 | Active |
| US11578130B2 | Regulatable chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US10576076B2 | Pharmaceutical combination of everolimus with dactolisib | Human Necessities | 0 | Active |
| US12214037B2 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US11591404B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US10703819B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US11459390B2 | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.